In the comparator group of the FLAURA trial, PD-L1 expressers had a 71% response rate and 6.9 month median duration in their response to EGFR-TKIs; this result indicates that positive PD-L1 expression did not affect the efficacy of gefitinib and erlotinib in treating EGFR-mutated NSCLC patients [28]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.